Zogenix to Participate in the Raymond James Institutional Investors Conference

Rhea-AI Summary

Zogenix, a biopharmaceutical company focused on rare disease therapies, announced that Michael Smith, CFO, will present a corporate overview at the Raymond James Institutional Investors Conference on March 3, 2021, at 3:50 PM Eastern Time. The presentation will be available via live webcast and archived for 90 days on the company's Investor Relations website. Zogenix is known for its FDA-approved therapy FINTEPLA for Dravet syndrome and is advancing additional therapies for rare genetic disorders.

EMERYVILLE, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Michael Smith, Executive Vice President, Chief Financial Officer, and Treasurer, will present a corporate overview and participate in a fireside chat on Wednesday, March 3, 2021, at the Raymond James Institutional Investors Conference.

Zogenix Presentation Details
Date:	Wednesday, March 3, 2021
Time:	3:50 PM Eastern Time

The presentation will be webcast live and archived for 90 days on Zogenix's Investor Relations website at https://zogenixinc.gcs-web.com.

About Zogenix
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA^® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.

CONTACTS:

Zogenix
Melinda Baker
Senior Director, Corporate Communications
+1 (510) 788-8732 | corpcomms@zogenix.com

Investors
Brian Ritchie 
Managing Director, LifeSci Advisors LLC
+1 (212) 915-2578 | britchie@lifesciadvisors.com

Media
Stefanie Tuck, Vice President, Porter Novelli
+1 (978) 390-1394 | stefanie.tuck@porternovelli.com

FAQ

When is Zogenix presenting at the Raymond James Conference?

Zogenix will present on March 3, 2021, at 3:50 PM Eastern Time.

Who will represent Zogenix at the investors conference?

Michael Smith, the CFO of Zogenix, will present at the conference.

How can I watch Zogenix's presentation?

The presentation will be webcast live and archived for 90 days on Zogenix's Investor Relations website.

What is Zogenix known for?

Zogenix is known for its rare disease therapies, including the FDA-approved FINTEPLA for treating seizures associated with Dravet syndrome.

What therapies is Zogenix currently developing?

Zogenix is developing therapies for Dravet syndrome, Lennox-Gastaut syndrome, and TK2 deficiency.